ArticleFuture science OA2026
Fulminant disseminated strongyloidiasis mimicking inflammatory bowel disease: a case report.
Article in Future science OA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStrongyloidiasis is a gastrointestinal parasitic infection caused by
resultsA 33-year-old man, presented in December 2024 with severe acute colitis. Endoscopy and histopathology findings were consistent with inflammatory bowel disease (IBD). The patient was treated with intravenous corticosteroids and antibiotics, then maintained on tapering oral corticosteroids. Three months later, while on 20 mg/day prednisone equivalent, he was readmitted for another episode of severe acute colitis. Stool parasitology, stool culture, tissue cytomegalovirus (CMV) polymerase chain reaction (PCR), and DISCUSSION: This case highlights the potential diagnostic confusion between IBD and strongyloidiasis. It underscores the potentially fatal consequences of unrecognized chronic strongyloidiasis and supports systematic screening prior to immunosuppressive therapy in at-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.